anti-PD1 and anti-PD-L1 drugs treating NSCLC

March 26, 2013 Interviewed By Steven E. Greer, MD

UCLA’s Dr. Edward Garon discusses anti-PD1 and anti-PD-L1 drugs treating NSCLC in early trials, with remarkable tumor response rates.

This entry was posted in - Biotech, - Pharma, Oncology, UCLA. Bookmark the permalink.

Leave a Reply